Moderated Poster

Poster, Podium & Video Sessions

MP26-17: Urinary level of Monocyte Chemotactic Protein-1 (MCP-1) predicts the severity of symptom in patient with Overactive Bladder (OAB): Pilot Prospective study.

Saturday, May 13
7:00 AM - 9:00 AM
Location: BCEC: Room 160

Presentation Authors: Bilal Farhan*, Ahmed Ahmed, Kheira Bettir, Ko Young Hwii, Frank Zaldivair, Gamal Ghoniem, Irvine, CA

Introduction: This study aims to express urinary MCP-1 level in OAB patients before and after treatments, and to correlate the level of MCP-1 with severity of symptoms.

Methods: This was a prospective, single-blind study including 26 OAB patients (either newly diagnosed or off medications for 2 weeks). Each patient received after the first visit different OAB treatments (anticholinergic, B3 agonist and or neuromodulations). Two midstream urine samples were collected and tested for MCP-1 using ELISA; one before and the second after 12 weeks of treatments. Symptomatic responses to therapy were evaluated using different validated OAB questionnaires [Patient Perception Bladder Condition (PPBC) & Overactive Bladder Quality (OAB-q)]. MCP-1 level were normalized to the levels of creatinine. Descriptive statistics were performed to examine MCP-1 level before and after different using Wilconxon test. Post-treatment MCP1- levels compared to 12 healthy subjects as control using Mann-Whitney U test.

Results: The mean age of enrolled 26 patients was 69.3yrs. Females accounted for 62.5% of patients. In simple correlation, the degrees of symptoms was significantly associated with the pre-treatment level of MCP-1 (coefficient=.844, p<.000 in PPBC and coefficient=.869, p<.000 in OABq, Figure 1). Mulivariate analysis using linear regression model including age, gender and MCP-1 demonstrated that MCP-1 was significantly associated with OABq (p=.02) and PPBC (p=.03). Twelve weeks after treatment, MCP-1 level was dropped significantly (p<.000), and it was similar with control group (p=0.376, Table). After treatment, the symptom improved significantly both in OAB-q and PPBC (Figure 2).

Conclusions: Based on a strong association with the degree of symptom, urinary MPC-1 can be used to identify patients and monitor the progression of OAB.

Source Of Funding: none

Bilal Farhan, MD

University Of California, Irvine

Bilal Farhan, MD. clinical fellow in Female Urology and Voiding dysfunction at University of California , Irvine.
He completed his residency training at Jordanian University of Science and Technology in King Abdullah University Hospital in Department of Urology for five years.
Eminently qualified, Dr. Farhan earned his medical degree from Al Qadisiyah University in Iraq with high honors from School of Medicine in Iraq. He completed an extensive internship in King Abdullah Univeristy Hospital in Urology training in Jordan.

He is Board certified with high Honor from Arab Board of Urology and from Jordanian Board of Urology.
His research interests involve the development of a comprehensive understanding of key developmental clinical pathways and pathophysiology of overactive bladder disease. His academic training and research experience to date have provided him with a good background in urinary cytokines that can involve in overactive bladder syndrome. He have a lot of publications in female urology and voiding dysfunction.

All of his life, he have striven to be the best that I can be and will continue to do so.

Presentation(s):

Send Email for Bilal Farhan


Assets

MP26-17: Urinary level of Monocyte Chemotactic Protein-1 (MCP-1) predicts the severity of symptom in patient with Overactive Bladder (OAB): Pilot Prospective study.



Attendees who have favorited this

Send Email for Urinary level of Monocyte Chemotactic Protein-1 (MCP-1) predicts the severity of symptom in patient with Overactive Bladder (OAB): Pilot Prospective study.